Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Patient Education Webcasts
COVID Updates: Where We Are and Where We Go From Here
Research
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Planegg/Munich, Germany, December 11, 2022 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study,…
Research
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at ASH Annual Meeting
SAN DIEGO, Dec. 10, 2022 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precis…
Research
Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Heidelberg, Germany, December 10, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed…
Research
Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update
TURKU, FINLAND / BOSTON, MA - December 5, 2022 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company …
News
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
Research
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Marseille, France, November 11, 2022 – ImCheck Therapeutics presented today the first patient data from EVICTION-2, a Phase I/II clinical trial evalua…
Research
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
BOSTON, Nov. 29, 2022 - X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit …
Research
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
BERKELEY, CA, Nov. 29, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, toda…
News
The Leukemia & Lymphoma Society’s Presence at ASH Showcases Progress to Advance Cures and Care for Blood Cancer Patients
At the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13), The Leukemia & Lymphoma Society (LLS) will be presenting new …
Professional Education Webcasts
Blood Cancer 101: The Basics on Disease, Treatment, and the Role of the HCP
This activity is intended for oncology social workers, psychologists, nurses, and other healthcare professionals involved in the care of patients with…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
